A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Methodology Development Environmental Clinical Trial With Reproxalap Ophthalmic Solutions (0.25% and 0.5%) in Subjects With Seasonal Allergic Conjunctivitis
Phase of Trial: Phase I/II
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs Reproxalap (Primary)
- Indications Allergic conjunctivitis
- Focus Therapeutic Use
- Sponsors Aldeyra Therapeutics
- 10 Jul 2019 Status changed from recruiting to completed.
- 03 Oct 2018 Status changed from not yet recruiting to recruiting.
- 12 Sep 2018 New trial record